http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Kana Yamanashi ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Kensuke Sakurai ),( Shigeru Furukawa ),( Takehiko Katsurada ),( Shinsuke Otagiri ),( Kana Yamanashi ),( Kazunori Nagashima ),( Reizo Onishi ),( Keiji Yagisawa ),( Haruto Nishimura ),( Takahiro Ito ) 대한장연구학회 2022 Intestinal Research Vol.20 No.1
Background/Aims: Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc defi ciency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine the effectiveness of zinc acetate hydrate (ZAH; Nobelzin) in IBD patients with zinc deficiency. Methods: IBD patients with zinc de ficiency who received ZAH from March 2017 to April 2020 were registered in this 2-center, retrospective, observational study. Changes in serum zinc levels and disease activity (Crohn’s Disease Activity Index [CDAI]) before and after ZAH administration were analyzed. Results: Fifty-one patients with Crohn’s disease (CD, n=40) or ulcerative colitis (UC, n=11) were registered. Median serum zinc level and median CDAI scores significantly improved (55.5-91.0 μg/dL, P<0.001; 171.5-129, P<0.001, respectively) in CD patients 4 weeks after starting ZAH administration. Similarly, median serum zinc levels and CDAI scores significantly improved (57.0-81.0 μg/dL, P<0.001; 177-148, P=0.012, respectively) 20 weeks after starting ZAH administra tion. Similar investigations were conducted in groups where no treatment change, other than ZAH administration, was imple mented; significant improvements were observed in both serum zinc level and CDAI scores. Median serum zinc levels in UC patients 4 weeks after starting ZAH administration significantly improved from 63.0 to 94.0 μg/dL (P=0.002), but no significant changes in disease activity were observed. One patient experienced side effects of abdominal discomfort and nausea. Conclu sions: ZAH administration is effective in improving zinc deficiency and may contribute to improving disease activity in IBD. (Intest Res 2022;20:78-89)
-
Effectiveness of transabdominal ultrasonography in predicting clinical relapse of Crohn’s disease
Shinya Fukushima,Takehiko Katsurada,Mutsumi Nishida,Satomi Omotehara,Kensuke Sakurai,Kana Yamanashi,Reizo Onishi,Naoya Sakamoto 대한장연구학회 2024 Intestinal Research Vol.22 No.1
Background/Aims: Transabdominal ultrasonography (US) helps evaluate Crohn’s disease (CD) activity. We investigated whether the US could predict subsequent adverse outcomes for patients with CD in clinical remission.Methods: This single-center retrospective study included patients with CD in clinical remission who underwent US between April 2011 and April 2021, focusing on the predictability of subsequent adverse outcomes within 5 years. We used the US-CD, which was calculated using multiple US findings. Predictive variables were assessed using Cox proportional hazards regression analysis, and the predictive value was evaluated using receiver operating characteristic curves.Results: Seventy-three patients were included. During a median follow-up of 1,441 days (range, 41–1,825 days), 16.4% (12/73) experienced clinical relapse, 9.6% (7/73) required endoscopic balloon dilation (EBD), 58.9% (43/73) required enhanced treatment, and 20.5% (15/73) underwent surgery. In the multivariate analysis, US-CD was significantly associated with clinical relapse (<i>P</i>= 0.038) and the need for enhanced treatment (<i>P</i>= 0.005). The area under the receiver operating characteristic curve for predicting clinical relapse and the need for EBD was 0.77 and 0.81, respectively, with US-CD (cutoff value = 11), and that for requiring enhanced treatment was 0.74 with US-CD (cutoff value = 6). Patients with US-CD ≥ 11 demonstrated a significantly higher occurrence of clinical relapse (<i>P</i>= 0.001) and EBD (<i>P</i>= 0.002) within 5 years. Patients with US-CD ≥ 6 experienced a significantly higher likelihood of requiring enhanced treatment (<i>P</i>< 0.001) within 5 years.Conclusions: High US-CD is associated with subsequent adverse outcomes in patients with CD.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
